The mission of the NRG Oncology Statistics and Data Management Center (SDMC) is to provide all necessary expertise and personnel for the design, conduct and analysis of clinical trials and associated research for NRG Oncology, a member group of the NCI National Clinical Trials Network (NCTN) program. The Statistics Core of the SDMC provides statistical methodology expertise for the conduct of cancer clinical trials and associated research. The Statistics Core is an integral component central to the SDMC and to NRG Oncology as a whole. Statisticians represent the most closely collaborating group within the SDMC with NRG Oncology investigators across the disease sites that the group addresses. In the first cycle (2014-2019) of the NCTN, the NRG Oncology SDMC was successfully formed from existent centers with specific areas of expertise, both in the disease sites and the attendant trial methodology. The SDMC has retained this expertise, but also broadened individuals? roles so that statisticians may engage in new disease sites, trial methodology, and analytic methods. This unification and expansion has strengthened the statistics group. During the first cycle, the statistics group enjoyed a highly productive period, supporting the initiation of 32 new trials and obtaining final approval on an additional 14 trials now in development, while continuing to maintain accrual and/or follow-up to primary and secondary endpoint reporting on over 80 additional trials that were active at the inception of NRG Oncology. With respect to contributions to the total NCTN effort, the accruing NRG Oncology trials during 2014-2017 represent 34% of all accruing NCTN trials. Publications from the group in the first cycle number over 300, including 39 statistics and clinical trials methodology articles by SDMC statisticians. In the second cycle of the NCTN, the Statistics Core will continue to carry out its critical trial conduct functions, beginning with trial design appropriate for the question, using innovative modern methods to develop efficient and maximally informative trials. Approaches such as integrated trial developmental phases and incorporation of modern biomarker-based information will be sought. Analysis plans for primary, secondary, and exploratory aims will reflect state-of-the-art statistical methodology, with novel methods developed as needed. The Statistics Core, working with other components of the SDMC, will provide continuous trial conduct oversight through all stages from concept and protocol development, trial monitoring, initial reporting, and publication. The statisticians will work closely with SDMC data management and information technology personnel to assure secure high-quality data collection, maintenance, and curation for additional discovery and data sharing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA180822-06
Application #
9628263
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-03-28
Budget End
2020-02-29
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47
Cho, Youngjoo; Hu, Chen; Ghosh, Debashis (2018) Covariate adjustment using propensity scores for dependent censoring problems in the accelerated failure time model. Stat Med 37:390-404
Dignam, James J; Hamstra, Daniel A; Lepor, Herbert et al. (2018) Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202. J Clin Oncol :JCO1800154
Roach, Mack; Moughan, Jennifer; Lawton, Colleen A F et al. (2018) Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol 19:1504-1515
Videtic, Gregory M; Paulus, Rebecca; Singh, Anurag K et al. (2018) Long term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase II study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys :
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2018) Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol :JCO2018788620
Tew, William P; Sill, Michael W; Walker, Joan L et al. (2018) Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol 151:257-263
Timmerman, Robert D; Paulus, Rebecca; Pass, Harvey I et al. (2018) Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. JAMA Oncol 4:1263-1266
Richardson, Debra L; Sill, Michael W; Coleman, Robert L et al. (2018) Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol 4:196-202
Regine, William F; Winter, Kathryn; Abrams, Ross A et al. (2018) Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol 3:154-162

Showing the most recent 10 out of 331 publications